Nearly a quarter of all newly-diagnosed patients with advanced lung cancer are not given a test that could improve their chances for long-term survival and reduce their side effects.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and challenges shaping SMMT's future.

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines, recently hosted the '2025 ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Rare, deadly, and often missed, some skin cancers develop in areas that rarely see the sun. Scientists are still learning about them, but here's what we know.

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Screening for disease, including cancer, can cause harm —during screening, diagnosis and treatment. With lung cancer ...

A study shows for the first time the relationship between this disease and the damage caused to DNA by breathing pollution.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Exposure to air pollution, other contaminants and traditional herbal medicines may be contributing to the development of lung ...